However, to date, investigations on blocking PPIs to understand their molecular mechanism are limited to in vitro biological investigations, but the availability of X-ray or NMR structures and biochemical assays would further facilitate medicinal chemistry studies of these PPI inhibitors in the treatment of MLL-rearranged leukemias. This evidence concerns the gene KMT2A and leukemia.